Skip to Content

Orgenesis Inc ORGS Stock Quote

| Rating as of


| Currency in USD

  • Last Close 0.59
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Value
  • Day Range 0.59  –  0.68
  • Year Range 0.38  –  2.59
  • Market Cap 19.1941 Mil
  • Volume / Avg 74,914.0 /  93,949.6
  • Price / Sales 0.44
  • Price / Book 0.70
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis ORGS

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ORGS

Company Profile ORGS

Business Description

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company’s business includes two reporting segments: Morgenesis and Therapies.

20271 Goldenrod Lane
Germantown, MD, 20876
Industry Biotechnology
Employees 167

Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.

Orgenesis Inc


Renovaro Biosciences Inc


Forma Therapeutics Holdings Inc Ordinary Shares


Molecular Templates Inc

+$0.04 (6.38%) +$0.05 (1.30%) +$0.15 (2.28%)
Market Cap
19.19 Mil248.42 Mil36.00 Mil
Biotechnology Biotechnology Biotechnology Biotechnology

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Orgenesis Inc Stock

No. ORGS does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ORGS’s market cap is 19.19 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ORGS’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ORGS’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ORGS’s historical performance against its industry peers and the overall market.